Cargando…

Molecular Theranostics in Radioiodine-Refractory Differentiated Thyroid Cancer

SIMPLE SUMMARY: Radioiodine therapy is the main treatment option for metastatic differentiated thyroid cancer (DTC). However, only half of these patients achieve (partial or complete) remission or have stable disease during long-term follow-up. In the remaining ones, disease progresses mainly as the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Petranović Ovčariček, Petra, Campenni, Alfredo, de Keizer, Bart, Deandreis, Desiree, Kreissl, Michael C., Vrachimis, Alexis, Tuncel, Murat, Giovanella, Luca
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10486510/ https://www.ncbi.nlm.nih.gov/pubmed/37686566 http://dx.doi.org/10.3390/cancers15174290

Ejemplares similares

Molecular Imaging and Theragnostics of Thyroid Cancers
por: Giovanella, Luca, et al.
Publicado: (2022)

Accuracy of papillary thyroid cancer prognostic nomograms: a systematic review
por: Luisa Garo, Maria, et al.
Publicado: (2023)

Postoperative thyroglobulin as a yard-stick for radioiodine therapy: decision tree analysis in a European multicenter series of 1317 patients with differentiated thyroid cancer
por: Giovanella, Luca, et al.
Publicado: (2023)

The EANM guideline on radioiodine therapy of benign thyroid disease
por: Campennì, Alfredo, et al.
Publicado: (2023)

Prevalence of thyroid dysfunction in patients with COVID-19: a systematic review
por: Giovanella, Luca, et al.
Publicado: (2021)

Thyroid Hormone Withdrawal versus Recombinant Human TSH as Preparation for I-131 Therapy in Patients with Metastatic Thyroid Cancer: A Systematic Review and Meta-Analysis
por: Giovanella, Luca, et al.
Publicado: (2023)

New! F-18-based PET/CT for sodium-iodine-symporter-targeted imaging!
por: Verburg, Frederik A., et al.
Publicado: (2020)

False-positive radioiodine uptake after radioiodine treatment in differentiated thyroid cancer
por: Barbaro, Daniele, et al.
Publicado: (2023)

Comparison of 1.1 GBq and 2.2 GBq Activities in Patients with Low-Risk Differentiated Thyroid Cancer Requiring Postoperative (131)I Administration: A Real Life Study
por: Campennì, Alfredo, et al.
Publicado: (2023)

Theranostic Options for Radioiodine-Refractory Differentiated Thyroid Carcinoma: Recent Advances, Challenges, and Road Ahead
por: Satapathy, Swayamjeet, et al.
Publicado: (2022)

Use of lenvatinib in the treatment of radioiodine-refractory differentiated thyroid cancer: a multidisciplinary perspective for daily practice
por: Capdevila, Jaume, et al.
Publicado: (2023)

ENDOCRINOLOGY IN THE TIME OF COVID-19: Management of thyroid nodules and cancer
por: Vrachimis, Alexis, et al.
Publicado: (2020)

Radioiodine therapy in differentiated thyroid cancer. There is (still) a great chaos under heaven: is the situation excellent?
por: Giovanella, Luca
Publicado: (2023)

Updated clinical management guidance during the COVID-19 pandemic: thyroid nodules and cancer
por: Giannoula, Evanthia, et al.
Publicado: (2022)

Diagnostic Performance of (99m)Tc-Methoxy-Isobuty-Isonitrile (MIBI) for Risk Stratification of Hypofunctioning Thyroid Nodules: A European Multicenter Study
por: Schenke, Simone Agnes, et al.
Publicado: (2022)

Radioiodine refractoriness score: A multivariable prediction model for postoperative radioiodine‐refractory differentiated thyroid carcinomas
por: Li, Genpeng, et al.
Publicado: (2018)

Personalized Medicine Based on Theranostic Radioiodine Molecular Imaging for Differentiated Thyroid Cancer
por: Ahn, Byeong-Cheol
Publicado: (2016)

Add-on radioiodine during long-term BRAF/MEK inhibition in patients with RAI-refractory thyroid cancers: a reasonable option?
por: Montes de Jesus, Filipe Miguel, et al.
Publicado: (2023)

Defining Radioiodine-Refractory Differentiated Thyroid Cancer: Efficacy and Safety of Lenvatinib by Radioiodine-Refractory Criteria in the SELECT Trial
por: Kiyota, Naomi, et al.
Publicado: (2017)

Feasibility of Apatinib in Radioiodine-Refractory Differentiated Thyroid Carcinoma
por: Du, Wei, et al.
Publicado: (2022)

Personalized management of differentiated thyroid cancer in real life – practical guidance from a multidisciplinary panel of experts
por: Campennì, Alfredo, et al.
Publicado: (2020)

Use of multikinase inhibitors/lenvatinib concomitant with radioiodine for the treatment of radioiodine refractory differentiated thyroid cancer
por: Herranz, Urbano Anido
Publicado: (2022)

Enhancing Radioiodine Incorporation into Radioiodine-Refractory Thyroid Cancer with MAPK Inhibition (ERRITI): A Single-Center Prospective Two-Arm Study
por: Weber, Manuel, et al.
Publicado: (2022)

Updates on the Management of Advanced, Metastatic, and Radioiodine Refractory Differentiated Thyroid Cancer
por: Tumino, Dario, et al.
Publicado: (2017)

(99m)Tc-Pertechnetate Scintigraphy Predicts Successful Postoperative Ablation in Differentiated Thyroid Carcinoma Patients Treated with Low Radioiodine Activities
por: Giovanella, Luca, et al.
Publicado: (2019)

Questions and Controversies in the Clinical Application of Tyrosine Kinase Inhibitors to Treat Patients with Radioiodine-Refractory Differentiated Thyroid Carcinoma: Expert Perspectives
por: Verburg, Frederik A., et al.
Publicado: (2021)

Safety and tolerability of sorafenib in patients with radioiodine-refractory thyroid cancer
por: Worden, Francis, et al.
Publicado: (2015)

Radioiodine Refractory Follicular Thyroid Cancer and Surgery for Cervical Relapse
por: Chiapponi, Costanza, et al.
Publicado: (2021)

New approaches for patients with advanced radioiodine-refractory thyroid cancer
por: Pitoia, Fabián, et al.
Publicado: (2022)

Management of Progressive Radioiodine-Refractory Thyroid Carcinoma: Current Perspective
por: Nervo, Alice, et al.
Publicado: (2022)

Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer for Reapplication of I-131 Therapy
por: Hong, Chae Moon, et al.
Publicado: (2017)

Cost-Effectiveness of Apatinib and Cabozantinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer
por: Shi, Bo, et al.
Publicado: (2022)

A user-friendly nomogram for predicting radioiodine refractory differentiated thyroid cancer
por: Meng, Chao, et al.
Publicado: (2023)

Overwhelming rapid metabolic and structural response to apatinib in radioiodine refractory differentiated thyroid cancer
por: Lin, Yansong, et al.
Publicado: (2017)

Theranostic role of radiolabelled RGD peptide in the treatment of radioiodine-resistant thyroid cancer: A novel agent
por: Vatsa, Rakhee, et al.
Publicado: (2020)

Ultrasound Assessment of Autonomous Thyroid Nodules before and after Radioiodine Therapy Using Thyroid Imaging Reporting and Data System (TIRADS)
por: Schenke, Simone Agnes, et al.
Publicado: (2020)

Exploring Theranostic Potentials of Radioiodinated Hypericin in Rodent Necrosis Models
por: Li, Junjie, et al.
Publicado: (2012)

Do Molecular Profiles of Primary Versus Metastatic Radioiodine Refractory Differentiated Thyroid Cancer Differ?
por: Gomes-Lima, Cristiane J., et al.
Publicado: (2021)

Clinical Indications for Treatment with Multi-Kinase Inhibitors in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer
por: Fukuda, Naoki, et al.
Publicado: (2021)

Ultrasound-guided implantation of radioactive (125)I seed in radioiodine refractory differentiated thyroid carcinoma
por: Chen, Wei, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hpfvf3o3mgbvsa9sk9r7h2ps03